Advertisement
ARGX vs VRTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGX is a Hold and VRTX is a Hold.
ARGX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for ARGX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 15 of the 20 cases the stock moved higher. This puts the odds of a move higher at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 218 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for ARGX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. ARGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.088) is normal, around the industry mean (26.823). P/E Ratio (29.519) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).
VRTX's RSI Oscillator ascends from oversold territory
The RSI Oscillator for VRTX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 13 of the 14 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 54 cases where VRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +4.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 238 of 368 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRTX as a result. In 43 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In 31 of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
VRTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.256) is normal, around the industry mean (26.823). P/E Ratio (28.870) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (438.009).
ARGX | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 22 | 19 | |
SMR RATING 1..100 | 41 | 41 | |
PRICE GROWTH RATING 1..100 | 71 | 45 | |
P/E GROWTH RATING 1..100 | 36 | 31 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VRTX's Valuation (82) in the Biotechnology industry is in the same range as ARGX (83) in the Pharmaceuticals Other industry. This means that VRTX’s stock grew similarly to ARGX’s over the last 12 months.
VRTX's Profit vs Risk Rating (19) in the Biotechnology industry is in the same range as ARGX (22) in the Pharmaceuticals Other industry. This means that VRTX’s stock grew similarly to ARGX’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is in the same range as ARGX (41) in the Pharmaceuticals Other industry. This means that VRTX’s stock grew similarly to ARGX’s over the last 12 months.
VRTX's Price Growth Rating (45) in the Biotechnology industry is in the same range as ARGX (71) in the Pharmaceuticals Other industry. This means that VRTX’s stock grew similarly to ARGX’s over the last 12 months.
VRTX's P/E Growth Rating (31) in the Biotechnology industry is in the same range as ARGX (36) in the Pharmaceuticals Other industry. This means that VRTX’s stock grew similarly to ARGX’s over the last 12 months.
| ARGX | VRTX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 75% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 71% | 3 days ago 69% |
| Momentum ODDS (%) | N/A | 3 days ago 49% |
| MACD ODDS (%) | N/A | 3 days ago 52% |
| TrendWeek ODDS (%) | 3 days ago 61% | 3 days ago 41% |
| TrendMonth ODDS (%) | 3 days ago 62% | 3 days ago 35% |
| Advances ODDS (%) | 4 days ago 71% | 4 days ago 65% |
| Declines ODDS (%) | 6 days ago 63% | 6 days ago 42% |
| BollingerBands ODDS (%) | 3 days ago 73% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 37% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARGX’s FA Score shows that 1 FA rating(s) are green while VRTX’s FA Score has 1 green FA rating(s).
- ARGX’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARGX’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 4 bullish TA indicator(s).
- ARGX’s TA Score: 4 bullish, 4 bearish.
- VRTX’s TA Score: 4 bullish, 6 bearish.
Price Growth
ARGX (@Biotechnology) experienced а -0.71% price change this week, while VRTX (@Biotechnology) price change was -2.03% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
ARGX is expected to report earnings on Oct 22, 2026.
VRTX is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement